At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 484 enrolled
Drug / intervention
Live F tularensis Vaccinebiological
Likely dose
Live F tularensis Vaccine 0.0025 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4
U.S. Army Medical Research and Development Command·interventional·Posted Jan 2, 2008·Updated Jan 2, 2020
In Brief
A Phase 2 clinical trial evaluating Live F tularensis Vaccine for Tularemia. Completed, enrolled 484 participants across 1 site.
Detailed Summary
This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTularemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedJan 2008
Primary CompletionOct 2009
Study CompletionOct 2013
TodayJul 2026
First PostedJan 2, 2008
Enrollment StartOct 1, 2004
Primary CompletionOct 1, 2009
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 18.5 years ago
Interventions
Live F tularensis Vaccinebiological
Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).